Drug intelligence / Profile preview

PF-06835375

Development stage: Phase 2
Lead developer: Pfizer
Modality: scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

PF-06835375 is a humanized, afucosyl immunoglobulin G1 (IgG1) monoclonal antibody developed by Pfizer. It acts as a selective antagonist of the C-X-C chemokine receptor type 5 (CXCR5), which is expressed on B cells, T follicular helper (Tfh) cells, and circulating Tfh-like (cTfh) cells. The drug depletes CXCR5-positive B and Tfh cells and antagonizes C-X-C motif chemokine ligand 13-dependent signaling, thereby modulating immune responses implicated in autoimmune diseases. Its primary indications under investigation include idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), and rheumatoid arthritis[1][4][7]. As of early 2024, it is in phase II clinical trials for ITP and phase I trials for SLE and rheumatoid arthritis[1].

Other names: PF 06835375PF06835375PF-06835375

Targets

CXCR5 (C-X-C motif chemokine receptor 5)

Beyond the preview

Go deeper on PF-06835375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06835375.

Explore the full profile